Ajla Wasti, MB BS

Ajla Wasti, MB BS

Hematology-Oncology

On staff since December 2018

"I strive to uphold standards of excellence in practice for our patients and their families as they navigate through challenging times with diagnosis and treatment. I consider myself privileged to be a small part of their journey and aim to have clinical interactions which are both thorough and thoughtful."

  • Other Publications

    • Wasti AT, Mandeville H, Gatz S, Chisholm JC
      Rhabdomyosarcoma
      Paediatrics and Child Health, 2018 April : 28(4)157-163
    • Rajagopalan KN, Egnatchik RA, Calvaruso MA, Wasti AT, Padanad MS, Boroughs LK, Ko B, Hensley CT, Acar M, Hu Z, Jiang L, Pascual JM, Scaglioni PP, DeBerardinis RJ
      Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells.
      26137220 Cancer & metabolism, 2015 : 37 PMCID:PMC4487196
    • Yang C, Ko B, Hensley CT, Jiang L, Wasti AT, Kim J, Sudderth J, Calvaruso MA, Lumata L, Mitsche M, Rutter J, Merritt ME, DeBerardinis RJ
      Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport.
      25458842 Molecular cell, 2014 Nov. 6 : 56(3)414-24 PMCID:PMC4268166
    • Hensley CT, Wasti AT, DeBerardinis RJ
      Glutamine and cancer: cell biology, physiology, and clinical opportunities.
      23999442 The Journal of clinical investigation, 2013 Sept. : 123(9)3678-84 PMCID:PMC3754270
    • Marsenic O, Wasti A, Yu Z, Couloures K, Henry D, Turman M
      Infant with gross hematuria and nephrotic syndrome: questions.
      21814728 Pediatric nephrology (Berlin, Germany), 2012 April : 27(4)563, 565-9

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

Shifa College of Medicine, Islambad
University of Oxford, Oxford

Residency

Pediatrics, University of Oklahoma Health Science Center, Oklahoma

Fellowship

Pediatric Hematology-Oncology, UT Southwestern Medical Center, Dallas

Clinical Interests

Pediatric sarcomas, early phase clinical trials, targeted therapy, immune checkpoint inhibition, pharmacovigilance, global cancer health disparities

Research Description